The Clear Labels Act’s path through the Senate Health, Education, Labor and Pensions Committee offers a working example of how legislative transparency mandates can be substantively altered through definitional and timeline revisions while preserving the surface architecture of the reform. Two original provisions — a unique facility identifier known as the DUNS number and a one-year compliance window — have been replaced with factory-address disclosure, a five-year implementation horizon, and the statutory term “place of business” rather than “factory.” Drug-safety researchers who spoke to ProPublica characterized those changes as a material reduction in the bill’s operational reach.

The analytical question the revisions raise is whether the new provisions perform the same function as the originals. Peter Baker, a former FDA inspector whose work involved companies affected by the bill, framed the trade-off directly: “The more flexibility they allow, the more complex it is to enforce it.” The DUNS number is a discrete, machine-readable identifier that the FDA already uses in its inspection files; a street address is a textual field that ProPublica’s reporting demonstrated can refer to multiple facilities or to entities other than the manufacturing site itself. When the newsroom built its Rx Inspector database, it was able to connect a drug to a specific facility directly in 69 percent of cases when the DUNS number was available, and had to rely on automated address verification, geolocation, and manual review when only addresses were available. The functional difference is the difference between a verifiable link and an inferential one — and the bill, as revised, has moved from the first to the second.

The conceptual-engineering counter to that characterization is that an address-only requirement, paired with narrow FDA rulemaking that defines “place of business” as the manufacturing site itself, could in principle produce traceability equivalent to the DUNS regime — provided the agency commits the inspection resources the bill does not authorize. The counter holds in principle; the substrate does not establish that the rulemaking record or the resource commitment will deliver it.

The term “place of business” rather than “factory” introduces a parallel function-failure. John Gray, an Ohio State University professor who testified before the Senate Special Committee on Aging led by Sens. Rick Scott and Kirsten Gillibrand, raised the concern in concrete terms: “If, in fact, ‘place of business’ can be interpreted as the location of the importer or the headquarters or something like that, it would be no different than what we have today. Then we’ll be right back to where we are. It’ll say ‘Manufactured for So-and-So in New York City,’ but it’s actually made somewhere else around the world.’” People familiar with the negotiations, as cited by ProPublica, said they are confident that manufacturers will not exploit such a loophole and that the FDA will have the final say on what counts as an acceptable address. That confidence rests on an agency whose inspection resources are already constrained — the same constraint Baker named when he observed that verifying address claims is more enforcement-burdensome than verifying a unique identifier.

The safety-research community’s response to the revisions is direct and on the record. “It’s just a clear watering down of the original bill,” said retired Army Col. Vic Suarez, a former medical supply-chain commander who has been leading a push for more domestic pharmaceutical manufacturing. Dr. Kevin Schulman, a Stanford University professor of medicine and health policy who has researched the economic pressures behind poor-quality generics, characterized the five-year window as effectively indefinite: “Five years after it passes might as well be a lifetime.” Baker said the five-year timeline is unnecessary: “If they wanted to do it in one year, they could.” “I would love to hear their justification on why they need five years to develop some rules and guidance on transparency. … I mean, it’s a simple label change,” Baker said.

The sponsors’ framing sits in tension with those characterizations. In a joint press release, Scott and Gillibrand praised the committee passage as a “massive win for consumer safety and transparency” but did not, in the press release or in statements reported by ProPublica, address the revisions. A representative from Gillibrand’s office said the five-year delay is intended to accommodate the FDA’s rulemaking process and label redesign by manufacturers. Read against the experts quoted above, the disagreement is not over whether transparency should occur but over what counts as transparency — and over what timeline.

The lobbying record on the industry side is documented. The Association for Accessible Medicines, the generic-drug industry’s trade group, previously told ProPublica the additional requirements would cause “significant costs in exchange for limited return.” The group’s public filings show it spent more than $1 million between January and July on healthcare and generics-related bills, including the Clear Labels Act. The trade group representing brand-name manufacturers did not respond to a request for comment; a spokesperson had previously said the industry would “welcome conversations about how to strengthen the biopharmaceutical supply chain.”

The dissent record on the Senate committee divides along two distinct framings, each with documentary depth. Sen. Maggie Hassan, D-N.H., raised national-security concerns about revealing the precise locations where lifesaving medications are manufactured — a concern the source reports was echoed in committee deliberations and that people familiar with the deliberations named as a factor in removing the DUNS identifier. Sen. Rand Paul, R-Ky., raised the contrary concern that additional labeling requirements could become an additional hurdle to drug production, on grounds that compliance costs and regulatory burdens could affect supply — a framing the source reports as his stated rationale for voting against the bill in committee, and that aligns with the trade association’s earlier public position that additional requirements would cause significant costs. Both framings rest on legitimate evidentiary grounds: the public-health record documented by ProPublica’s investigation into contaminated foreign factories and the documented record of industry cost objections in lobbying disclosures. The legislative process appears to have weighted Hassan’s national-security framing on the question of granularity (the DUNS identifier was removed) while accommodating the public-health framing on the question of disclosure itself (factory addresses remain required); Paul’s production-cost framing is consistent with the trade association’s position but did not, on the substrate, drive a specific textual change. The revised bill passed the committee in July with Paul as the sole dissenter.

The forward architecture of the revised bill contains a forecast that emerges from the integration of scenario and pre-mortem analysis. Two pathways are distinguishable from the substrate.

Pathway A — the strict-rulemaking pathway: FDA rulemaking interprets “place of business” narrowly to mean the manufacturing facility; manufacturers comply at the higher end of the distribution; address-only traceability performs at roughly the rate ProPublica’s address-only methodology achieved, the complement of the 69 percent direct-match rate the newsroom documented for DUNS-based traceability; inspection resources are stretched but not broken. This pathway delivers a public record that approximates, without replicating, the DUNS regime’s traceability, and the bill’s transparency language remains operational.

Pathway B — the deferred-enforcement pathway: the five-year compliance window functions as a horizon for negotiation over what “place of business” denotes; address-verification ambiguity produces records of limited traceability, particularly at multi-factory single-address sites in India that ProPublica documented; FDA inspection capacity, which Baker described as already overworked, becomes the binding constraint on enforcement rather than the statutory text. This pathway delivers the surface language of transparency without the operational reach of the original bill, and the cost of verification is transferred from the disclosure stage to the enforcement stage.

The substrate does not fix which pathway will obtain. The structural conditions align with Pathway B — a loosely defined statutory term, an extended compliance horizon, an under-resourced enforcement agency, and an industry with documented cost objections — but Pathway A is within the range of possible outcomes. The two pathways share a second-order characteristic that locates the bill’s analytical interest in the wicked-problems frame: there is no agreed stopping rule that tells either sponsors or critics when the revised text has produced adequate traceability. Stakeholder definitions of “adequate” diverge — Schulman’s “lifetime” critique, Baker’s “simple label change” framing, the sponsors’ “massive win” framing, and the trade association’s “significant costs” framing are incommensurable on a shared metric. The choice architecture is irreversible on the timeline the bill establishes, because a five-year compliance horizon closes off the question of whether the original DUNS regime would have been the appropriate instrument.

The national-security framing that senators raised during committee intersects this dynamic and creates the framing tension that makes the problem genuinely wicked. Baker, the former inspector, responded to that framing directly: “It’s a public health concern over a national security concern. I would say that those risks outweigh the national security concerns.” ProPublica’s reporting noted that Baker argued information about U.S. drug-manufacturing locations is already widely known. Both framings rest on legitimate evidentiary grounds — ProPublica’s investigation found that the United States had continued importing generic drugs from foreign factories after FDA inspectors identified quality and safety lapses at those sites, and the national-security concern about revealing the locations of lifesaving-drug production is a documented committee record. The legislative process appears to have weighted the national-security framing over the public-health framing on the question of granularity (the DUNS identifier) while accommodating the public-health framing on the question of disclosure itself (factory addresses remain required). That trade-off is the substance of the revision, and it is not resolvable by either framing on its own terms.

What the revised text suggests, when read against the original bill and against the documented enforcement record, is that the experts quoted in the substrate identify three structural choices through which legislative transparency is defined into or out of operational meaning: the identifier used, where the DUNS-to-address substitution carries Baker’s enforcement-burden argument; the entity required to be disclosed, where Gray’s “place of business” framing carries the definitional concern; and the compliance timeline, where Schulman’s “might as well be a lifetime” critique and Baker’s characterization of the change as “a simple label change” carry the timeline concern. The Clear Labels Act’s committee passage preserved the language of transparency while altering each of those instruments. Whether the revised bill’s transparency function survives the rulemaking process will depend on choices that have not yet been made — and on the inspection resources the bill does not authorize. The revision cost, in other words, has been transferred from the disclosure stage to the enforcement stage, where the agency’s capacity is already the limiting factor the original bill’s identifier was designed to work around.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Conceptual Engineering
Asks not just what a concept means but what it should mean, and re-engineers it.
Wicked Futures
Explores a long-horizon, deeply entangled future with no clean resolution.
Wicked Problems
Treats a problem as wicked — no stopping rule, no clean test of success, every attempt consequential.